CJ-42794

CJ-42794 (CJ-042794) is a potent, orally active, selective prostaglandin E receptor 4 (EP4) antagonist with an IC50 value of 10 nM, which is 200-fold more selective than EP1, EP2 and EP3. CJ-42794 can be used in research of gastric ulcers[1][2].

Product Specifications

CAS Number

[847728-01-2]

Product Name Alternative

CJ-042794

UNSPSC

12352005

Hazard Statement

H317-H319

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/CJ-42794.html

Concentration

10mM

Purity

98.96

Solubility

DMSO : ≥ 28 mg/mL

Smiles

ClC1=CC=C(OC2=CC=C(F)C=C2)C(C(N[C@H](C3=CC=C(C(O)=O)C=C3)C)=O)=C1

Molecular Formula

C22H17ClFNO4

Molecular Weight

413.83

Precautions

P261-P264-P272-P280-P302+P352-P305+P351+P338-P362+P364-P501

References & Citations

[1]Murase A, et, al. In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP (4) receptor antagonist. Life Sci. 2008 Jan 16;82 (3-4) :226-32.|[2]Takeuchi K, et, al. Effect of (S) -4- (1- (5-chloro-2- (4-fluorophenyoxy) benzamido) ethyl) benzoic acid (CJ-42794), a selective antagonist of prostaglandin E receptor subtype 4, on ulcerogenic and healing responses in rat gastrointestinal mucosa. J Pharmacol Exp Ther. 2007 Sep;322 (3) :903-12.